ERBB2 and breast cancer: In addition, it has been shown that the presence of TILs may be capable of predicting outcome and response to treatment in early TN and HER2+ diseases, thus underlying that the biology of these aggressive BC subtypes may be deeply affected by the immune counterpart of tumor microenvironment [3–6].